View ValuationSynBiotic 향후 성장Future 기준 점검 5/6SynBiotic (는) 각각 연간 72.4% 및 27.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 76.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -4.9% 로 예상됩니다.핵심 정보72.4%이익 성장률76.09%EPS 성장률Pharmaceuticals 이익 성장23.9%매출 성장률27.2%향후 자기자본이익률-4.90%애널리스트 커버리지Low마지막 업데이트19 Dec 2025최근 향후 성장 업데이트Price Target Changed • Nov 27Price target decreased by 45% to €6.50Down from €11.80, the current price target is an average from 2 analysts. New target price is 224% above last closing price of €2.01. Stock is down 64% over the past year. The company is forecast to post a net loss per share of €0.33 next year compared to a net loss per share of €2.24 last year.Price Target Changed • Sep 08Price target decreased by 28% to €11.80Down from €16.30, the current price target is provided by 1 analyst. New target price is 297% above last closing price of €2.98. Stock is down 42% over the past year. The company is forecast to post a net loss per share of €0.44 next year compared to a net loss per share of €2.24 last year.Price Target Changed • Dec 27Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 183% above last closing price of €4.40. Stock is up 47% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.Price Target Changed • Nov 20Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 123% above last closing price of €5.58. Stock is up 89% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.Breakeven Date Change • May 31No longer forecast to breakevenThe analyst covering SynBiotic no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €50.0k in 2023. New forecast suggests the company will make a loss of €2.10m in 2023.Price Target Changed • Apr 13Price target increased by 28% to €75.00Up from €58.50, the current price target is provided by 1 analyst. New target price is 859% above last closing price of €7.82. Stock is down 58% over the past year. The company is forecast to post a net loss per share of €0.19 next year compared to a net loss per share of €4.15 last year.모든 업데이트 보기Recent updates공시 • Mar 18SynBiotic SE, Annual General Meeting, Apr 23, 2026SynBiotic SE, Annual General Meeting, Apr 23, 2026, at 10:00 W. Europe Standard Time.Board Change • Mar 09No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Feb 10No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Jan 26No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Price Target Changed • Nov 27Price target decreased by 45% to €6.50Down from €11.80, the current price target is an average from 2 analysts. New target price is 224% above last closing price of €2.01. Stock is down 64% over the past year. The company is forecast to post a net loss per share of €0.33 next year compared to a net loss per share of €2.24 last year.Board Change • Nov 27No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Sep 08No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Price Target Changed • Sep 08Price target decreased by 28% to €11.80Down from €16.30, the current price target is provided by 1 analyst. New target price is 297% above last closing price of €2.98. Stock is down 42% over the past year. The company is forecast to post a net loss per share of €0.44 next year compared to a net loss per share of €2.24 last year.New Risk • Jul 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€24.5m market cap, or US$28.8m).Board Change • Jun 18No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.공시 • Apr 19SynBiotic SE announced that it expects to receive €2.4 million in fundingSynBiotic SE announced a private placement that it will issue non-interest-bearing convertible bonds for the gross proceeds of up to €2,400,000 on April 17, 2025. The company will issue in several tranches of up to €200,000 each. The issue of the first convertible bonds is scheduled to start at the end of April 2025.New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Revenue is less than US$5m (€3.9m revenue, or US$4.4m). Market cap is less than US$100m (€21.2m market cap, or US$24.1m).Board Change • Mar 28No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Feb 12No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Price Target Changed • Dec 27Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 183% above last closing price of €4.40. Stock is up 47% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.Board Change • Dec 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Price Target Changed • Nov 20Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 123% above last closing price of €5.58. Stock is up 89% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.Board Change • Nov 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman of Advisory Board Bruce Linton was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Aug 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.9m free cash flow). Earnings have declined by 49% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Revenue is less than US$5m (€4.1m revenue, or US$4.5m). Market cap is less than US$100m (€31.6m market cap, or US$35.1m).공시 • Aug 15SynBiotic SE, Annual General Meeting, Sep 20, 2024SynBiotic SE, Annual General Meeting, Sep 20, 2024, at 10:00 W. Europe Standard Time.New Risk • Aug 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€34.5m market cap, or US$37.9m).New Risk • Jul 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Market cap is less than US$100m (€37.7m market cap, or US$40.4m).New Risk • Jun 21New major risk - Revenue and earnings growthRevenue has declined by 9.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€35.6m market cap, or US$38.0m).New Risk • Mar 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (31% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€400k net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (€35.8m market cap, or US$39.2m).Board Change • Oct 11No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (4 non-independent directors). Chairman of the Board of Directors Sebastian Stietzel is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.New Risk • Jul 02New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risks Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (€21.1m market cap, or US$23.0m).Breakeven Date Change • May 31No longer forecast to breakevenThe analyst covering SynBiotic no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €50.0k in 2023. New forecast suggests the company will make a loss of €2.10m in 2023.Price Target Changed • Apr 13Price target increased by 28% to €75.00Up from €58.50, the current price target is provided by 1 analyst. New target price is 859% above last closing price of €7.82. Stock is down 58% over the past year. The company is forecast to post a net loss per share of €0.19 next year compared to a net loss per share of €4.15 last year.공시 • Nov 25SynBiotic SE Appoints Bruce Linton as Chairman of Newly Created Advisory BoardSynBiotic SE, accelerates implementation of the operational platform to achieve market leadership in the upcoming national legalization of recreational cannabis by securing Bruce Linton to its team. Mr. Linton is one of the most experienced and most successful cannabis entrepreneurs and investors globally and has been the driving force behind the creation of multiple global multi-billion dollar cannabis enterprises, several of them listed on NYSE, Nasdaq, TSX, TSX:V, CSE and ASX. Most notably, Mr. Linton is the founder and former Chairman and CEO of the global cannabis company Canopy Growth Corporation, which, at the time of his departure, had a market valuation of approximately CAD 20 billion and more than 25% market share in the Canadian recreational market while also being a global top tier supplier. Canopy was the first North American supplier to the German medical cannabis market. Combining unparalleled expertise in the areas of both medical and recreational cannabis, Mr. Linton is a powerful asset given SynBiotic's expansion plans, which cover both segments. Mr. Linton has been appointed as Chairman of SynBiotic's newly created Advisory Board and has invested capital in the company's most recent financing round. His investment plus options to buy further shares from existing shareholders will bring him to an ownership of approx. 5% in SynBiotic.Board Change • Nov 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Sep 02SynBiotic SE Launches Full-Line Medical Cannabis BrandSynBiotic SE launches full-line medical cannabis brand. In mid-September, the pharmacy market is due to attend Expopharm, the most important leading European trade fair. SynBiotic SE will present its new brand Hempamed Rx at its own booth. Europe's largest listed corporate group in the hemp and cannabis sector is launching an extensive range of full-spectrum extracts, dronabinol and various flowers. In this process, canna.sales GmbH becomes SynBiotic Sales GmbH, with a fifteen-person field sales team consisting of employees with many years of experience in the field of medical cannabis, and GECA Pharma GmbH, responsible for the import and distribution of medical cannabis products, becomes SynBiotic Distribution GmbH. Sales offensive in the field of medical cannabis: While other cannabis companies are downsizing their sales teams and seemingly fully concentrate on the legalization of recreational use, are keeping a firm eye on all areas of the existing and future cannabis market," says Lars Müller, CEO of SynBiotic SE. The goal: to provide competent advice throughout Germany. With the sales offensive, the Munich-based corporate group wants to underline its clear vision in the wake of increasing treatments and prescriptions for medical cannabis. Products from this area can be used to treat chronic pain, among other things. In particular, patients suffering from depression and anxiety/sleep disorders, but also Tourette's, MS or epilepsy, can alleviate their symptoms and the resulting pain through the use of medical cannabis. Strong pipeline: Unprecedented product innovations: SynBiotic SE will build up further capacities in the important field of medical cannabis and further expand its dominant position not only on the distribution side. The launch of Hempamed Rx also culminates years of research and development of innovative products that will be launched under the new brand in the coming weeks and months. Particularly in the field of medical cannabis, it is important to enable treatments that are optimally adapted to individual complaints. The dosage forms in particular make an important contribution to this. In order to enable everyone to benefit from the advantages of medical cannabis, SynBiotic SE is constantly expanding its product portfolio through the use of various carrier substances. The high bio-availability is as much in focus as the good tolerability of the products.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Breakeven Date Change • Aug 27Forecast to breakeven in 2022The analyst covering SynBiotic expects the company to break even for the first time. New forecast suggests the company will make a profit of €1.70m in 2022. Average annual earnings growth of 93% is required to achieve expected profit on schedule.Is New 90 Day High Low • Jan 11New 90-day high: €25.60The company is up 51% from its price of €17.00 on 13 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period.Is New 90 Day High Low • Dec 03New 90-day high: €20.20The company is up 13% from its price of €17.90 on 04 September 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.Is New 90 Day High Low • Nov 03New 90-day low: €13.90The company is down 15% from its price of €16.40 on 04 August 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period.Is New 90 Day High Low • Oct 08New 90-day low: €14.10The company is down 21% from its price of €17.90 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 8.0% over the same period.공시 • Oct 08SynBiotic SE (DUSE:L3D) acquired 25% stake in GreenLight Pharmaceuticals Ltd.SynBiotic SE (DUSE:L3D) acquired 25% stake in GreenLight Pharmaceuticals Ltd on October 6, 2020. In addition to the acquired share, SynBiotic also receives the option to strengthen its commitment in the future through further shares. SynBiotic SE (DUSE:L3D) completed the acquisition of 25% stake in GreenLight Pharmaceuticals Ltd on October 6, 2020.공시 • Sep 22SynBiotic SE (DUSE:L3D) entered into an agreement to acquire BioCBD E-commerce business of Umtr Group LimitedSynBiotic SE (DUSE:L3D) entered into an agreement to acquire BioCBD E-commerce business of Umtr Group Limited on September 21, 2020. Under the terms of transaction, certain tangible and intangible assets as well as the Umtr Group's customer base relating to BioCBD e-commerce are to be taken over by SynBiotic SE. The purchase price is to be paid partly in cash and partly in cash or in shares and comprises a total of a low single-digit million amount. Major part of purchase price can be paid in exchange for shares of SynBiotic.이익 및 매출 성장 예측DUSE:SBX - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202724N/A00212/31/202619-1-10212/31/202516-2-1-1212/31/202416-2-3-3212/31/20234-11-3-3N/A12/31/20228-24-7-7N/A12/31/20219-13-6-5N/A12/31/20205-1-3-1N/A12/31/2019N/A000N/A애널리스트 향후 성장 전망수입 대 저축률: SBX 의 연간 예상 수익 증가율(72.4%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: SBX 의 연간 수익(72.4%)이 German 시장(17%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: SBX 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: SBX 의 수익(연간 27.2%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: SBX 의 수익(연간 27.2%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SBX는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 16:35종가2026/03/09 00:00수익2023/12/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스SynBiotic SE는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Harald Hofmwb research AGChristian SandherrNuWays AG
Price Target Changed • Nov 27Price target decreased by 45% to €6.50Down from €11.80, the current price target is an average from 2 analysts. New target price is 224% above last closing price of €2.01. Stock is down 64% over the past year. The company is forecast to post a net loss per share of €0.33 next year compared to a net loss per share of €2.24 last year.
Price Target Changed • Sep 08Price target decreased by 28% to €11.80Down from €16.30, the current price target is provided by 1 analyst. New target price is 297% above last closing price of €2.98. Stock is down 42% over the past year. The company is forecast to post a net loss per share of €0.44 next year compared to a net loss per share of €2.24 last year.
Price Target Changed • Dec 27Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 183% above last closing price of €4.40. Stock is up 47% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.
Price Target Changed • Nov 20Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 123% above last closing price of €5.58. Stock is up 89% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.
Breakeven Date Change • May 31No longer forecast to breakevenThe analyst covering SynBiotic no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €50.0k in 2023. New forecast suggests the company will make a loss of €2.10m in 2023.
Price Target Changed • Apr 13Price target increased by 28% to €75.00Up from €58.50, the current price target is provided by 1 analyst. New target price is 859% above last closing price of €7.82. Stock is down 58% over the past year. The company is forecast to post a net loss per share of €0.19 next year compared to a net loss per share of €4.15 last year.
공시 • Mar 18SynBiotic SE, Annual General Meeting, Apr 23, 2026SynBiotic SE, Annual General Meeting, Apr 23, 2026, at 10:00 W. Europe Standard Time.
Board Change • Mar 09No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Feb 10No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Jan 26No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Price Target Changed • Nov 27Price target decreased by 45% to €6.50Down from €11.80, the current price target is an average from 2 analysts. New target price is 224% above last closing price of €2.01. Stock is down 64% over the past year. The company is forecast to post a net loss per share of €0.33 next year compared to a net loss per share of €2.24 last year.
Board Change • Nov 27No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Sep 08No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Price Target Changed • Sep 08Price target decreased by 28% to €11.80Down from €16.30, the current price target is provided by 1 analyst. New target price is 297% above last closing price of €2.98. Stock is down 42% over the past year. The company is forecast to post a net loss per share of €0.44 next year compared to a net loss per share of €2.24 last year.
New Risk • Jul 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€24.5m market cap, or US$28.8m).
Board Change • Jun 18No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
공시 • Apr 19SynBiotic SE announced that it expects to receive €2.4 million in fundingSynBiotic SE announced a private placement that it will issue non-interest-bearing convertible bonds for the gross proceeds of up to €2,400,000 on April 17, 2025. The company will issue in several tranches of up to €200,000 each. The issue of the first convertible bonds is scheduled to start at the end of April 2025.
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Revenue is less than US$5m (€3.9m revenue, or US$4.4m). Market cap is less than US$100m (€21.2m market cap, or US$24.1m).
Board Change • Mar 28No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Feb 12No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Price Target Changed • Dec 27Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 183% above last closing price of €4.40. Stock is up 47% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.
Board Change • Dec 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Price Target Changed • Nov 20Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 123% above last closing price of €5.58. Stock is up 89% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.
Board Change • Nov 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman of Advisory Board Bruce Linton was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Aug 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.9m free cash flow). Earnings have declined by 49% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Revenue is less than US$5m (€4.1m revenue, or US$4.5m). Market cap is less than US$100m (€31.6m market cap, or US$35.1m).
공시 • Aug 15SynBiotic SE, Annual General Meeting, Sep 20, 2024SynBiotic SE, Annual General Meeting, Sep 20, 2024, at 10:00 W. Europe Standard Time.
New Risk • Aug 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€34.5m market cap, or US$37.9m).
New Risk • Jul 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Market cap is less than US$100m (€37.7m market cap, or US$40.4m).
New Risk • Jun 21New major risk - Revenue and earnings growthRevenue has declined by 9.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€35.6m market cap, or US$38.0m).
New Risk • Mar 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (31% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€400k net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (€35.8m market cap, or US$39.2m).
Board Change • Oct 11No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (4 non-independent directors). Chairman of the Board of Directors Sebastian Stietzel is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
New Risk • Jul 02New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risks Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (€21.1m market cap, or US$23.0m).
Breakeven Date Change • May 31No longer forecast to breakevenThe analyst covering SynBiotic no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €50.0k in 2023. New forecast suggests the company will make a loss of €2.10m in 2023.
Price Target Changed • Apr 13Price target increased by 28% to €75.00Up from €58.50, the current price target is provided by 1 analyst. New target price is 859% above last closing price of €7.82. Stock is down 58% over the past year. The company is forecast to post a net loss per share of €0.19 next year compared to a net loss per share of €4.15 last year.
공시 • Nov 25SynBiotic SE Appoints Bruce Linton as Chairman of Newly Created Advisory BoardSynBiotic SE, accelerates implementation of the operational platform to achieve market leadership in the upcoming national legalization of recreational cannabis by securing Bruce Linton to its team. Mr. Linton is one of the most experienced and most successful cannabis entrepreneurs and investors globally and has been the driving force behind the creation of multiple global multi-billion dollar cannabis enterprises, several of them listed on NYSE, Nasdaq, TSX, TSX:V, CSE and ASX. Most notably, Mr. Linton is the founder and former Chairman and CEO of the global cannabis company Canopy Growth Corporation, which, at the time of his departure, had a market valuation of approximately CAD 20 billion and more than 25% market share in the Canadian recreational market while also being a global top tier supplier. Canopy was the first North American supplier to the German medical cannabis market. Combining unparalleled expertise in the areas of both medical and recreational cannabis, Mr. Linton is a powerful asset given SynBiotic's expansion plans, which cover both segments. Mr. Linton has been appointed as Chairman of SynBiotic's newly created Advisory Board and has invested capital in the company's most recent financing round. His investment plus options to buy further shares from existing shareholders will bring him to an ownership of approx. 5% in SynBiotic.
Board Change • Nov 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Sep 02SynBiotic SE Launches Full-Line Medical Cannabis BrandSynBiotic SE launches full-line medical cannabis brand. In mid-September, the pharmacy market is due to attend Expopharm, the most important leading European trade fair. SynBiotic SE will present its new brand Hempamed Rx at its own booth. Europe's largest listed corporate group in the hemp and cannabis sector is launching an extensive range of full-spectrum extracts, dronabinol and various flowers. In this process, canna.sales GmbH becomes SynBiotic Sales GmbH, with a fifteen-person field sales team consisting of employees with many years of experience in the field of medical cannabis, and GECA Pharma GmbH, responsible for the import and distribution of medical cannabis products, becomes SynBiotic Distribution GmbH. Sales offensive in the field of medical cannabis: While other cannabis companies are downsizing their sales teams and seemingly fully concentrate on the legalization of recreational use, are keeping a firm eye on all areas of the existing and future cannabis market," says Lars Müller, CEO of SynBiotic SE. The goal: to provide competent advice throughout Germany. With the sales offensive, the Munich-based corporate group wants to underline its clear vision in the wake of increasing treatments and prescriptions for medical cannabis. Products from this area can be used to treat chronic pain, among other things. In particular, patients suffering from depression and anxiety/sleep disorders, but also Tourette's, MS or epilepsy, can alleviate their symptoms and the resulting pain through the use of medical cannabis. Strong pipeline: Unprecedented product innovations: SynBiotic SE will build up further capacities in the important field of medical cannabis and further expand its dominant position not only on the distribution side. The launch of Hempamed Rx also culminates years of research and development of innovative products that will be launched under the new brand in the coming weeks and months. Particularly in the field of medical cannabis, it is important to enable treatments that are optimally adapted to individual complaints. The dosage forms in particular make an important contribution to this. In order to enable everyone to benefit from the advantages of medical cannabis, SynBiotic SE is constantly expanding its product portfolio through the use of various carrier substances. The high bio-availability is as much in focus as the good tolerability of the products.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Breakeven Date Change • Aug 27Forecast to breakeven in 2022The analyst covering SynBiotic expects the company to break even for the first time. New forecast suggests the company will make a profit of €1.70m in 2022. Average annual earnings growth of 93% is required to achieve expected profit on schedule.
Is New 90 Day High Low • Jan 11New 90-day high: €25.60The company is up 51% from its price of €17.00 on 13 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Dec 03New 90-day high: €20.20The company is up 13% from its price of €17.90 on 04 September 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Nov 03New 90-day low: €13.90The company is down 15% from its price of €16.40 on 04 August 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Oct 08New 90-day low: €14.10The company is down 21% from its price of €17.90 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 8.0% over the same period.
공시 • Oct 08SynBiotic SE (DUSE:L3D) acquired 25% stake in GreenLight Pharmaceuticals Ltd.SynBiotic SE (DUSE:L3D) acquired 25% stake in GreenLight Pharmaceuticals Ltd on October 6, 2020. In addition to the acquired share, SynBiotic also receives the option to strengthen its commitment in the future through further shares. SynBiotic SE (DUSE:L3D) completed the acquisition of 25% stake in GreenLight Pharmaceuticals Ltd on October 6, 2020.
공시 • Sep 22SynBiotic SE (DUSE:L3D) entered into an agreement to acquire BioCBD E-commerce business of Umtr Group LimitedSynBiotic SE (DUSE:L3D) entered into an agreement to acquire BioCBD E-commerce business of Umtr Group Limited on September 21, 2020. Under the terms of transaction, certain tangible and intangible assets as well as the Umtr Group's customer base relating to BioCBD e-commerce are to be taken over by SynBiotic SE. The purchase price is to be paid partly in cash and partly in cash or in shares and comprises a total of a low single-digit million amount. Major part of purchase price can be paid in exchange for shares of SynBiotic.